|
Video: What is a Stock Split?
|
|
Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. Co.'s approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. Co. refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE® drug delivery technology (ENHANZE). Co. licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. According to our Halozyme Therapeutics stock split history records, Halozyme Therapeutics has had 0 splits. | |
|
Halozyme Therapeutics (HALO) has 0 splits in our Halozyme Therapeutics stock split history database.
Looking at the Halozyme Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Halozyme Therapeutics shares, starting with a $10,000 purchase of HALO, presented on a split-history-adjusted basis factoring in the complete Halozyme Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$12.71 |
|
End price/share: |
$40.73 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
220.46% |
|
Average Annual Total Return: |
12.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$32,032.60 |
|
Years: |
10.00 |
|
|
|
|
|